Stockscreener 앱 받기
22.66
1.50%
0.265
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Definium Therapeutics (DFTX) Expands DT120 ODT Into PTSD Can Its Psychedelic Strategy Scale Across Psychiatry? - simplywall.st
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated May 2026 - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation As DT120 ODT Nears Key Phase 2 And Phase 3 Readouts - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 213% One Year Surge? - Sahm
Definium Therapeutics to hold live Q1 financial webcast on May 7 - Traders Union
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 - The Joplin Globe
A Look At Definium Therapeutics (DFTX) Valuation After Recent Share Price Volatility - Sahm
Definium Therapeutics (DFTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN
Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update - MarketBeat
Can Definium Therapeutics' (DFTX) LSD Platform Strategy Reframe Its Risk Profile Across Brain Health Disorders? - simplywall.st
Definium Therapeutics (STU:MMQ0) Shiller PE Ratio : (As of May. 02, 2026) - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Down 6.7%Here's What Happened - MarketBeat
Definium Therapeutics (DFTX) details 2026 virtual meeting and equity plan vote - Stock Titan
These 3 Psychedelic Stocks Activated After Trump’s Executive Order - Investing.com
These 3 Psychedelic Stocks Activated After Trump's Executive Order - MarketBeat
Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst - MSN
Q1 Earnings Estimate for DFTX Issued By HC Wainwright - MarketBeat
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Definium Therapeutics, Inc. (DFTX) Analyst/Investor DaySlideshow (NASDAQ:DFTX) 2026-04-24 - Seeking Alpha
Definium Therapeutics (DFTX) stock gains after hours: Here's what's driving the move - MSN
Definium Therapeutics : Investor & Analyst Day April 2026 - marketscreener.com
Definium Therapeutics Investor Day: DT120 Phase III Readouts Set for Late Q2–Q3, PTSD Plan for 2027 - Yahoo Finance
Stifel reiterates Definium Therapeutics stock rating on trial confidence - Investing.com UK
Stifel reiterates Definium Therapeutics stock rating on trial confidence By Investing.com - Investing.com Australia
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $28 to $70 - Moomoo
H.C. Wainwright reiterates Definium stock rating at buy on phase 3 progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Definium stock rating at buy on phase 3 progress - Investing.com
Definium Therapeutics (DFTX) Gets a Buy from H.C. Wainwright - The Globe and Mail
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 311% One Year Surge? - Sahm
Oppenheimer Adjusts Definium Therapeutics PT to $40 From $25, Maintains Outperform Rating - marketscreener.com
Piper Sandler reiterates Definium stock rating on development plan By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $28 to $49 - Moomoo
The Bull Case For Definium Therapeutics (DFTX) Could Change Following US Psychedelic Policy Momentum - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Definium expects three trial readouts for depression, anxiety drug By Investing.com - Investing.com India
DFTX (Definium Therapeutics Inc. Common Shares) posts narrow Q4 2025 EPS miss, trades slightly higher in today’s market session.Earnings Beat - Cổng thông tin điện tử tỉnh Lào Cai
Definium Therapeutics (DFTX) Advances Clinical Programs and Comm - GuruFocus
Definium expects three trial readouts for depression, anxiety drug - Investing.com
Definium Highlights DT120 Phase 3 Progress in Depression, Anxiety - TipRanks
Definium Therapeutics highlights advancement of DT120 ODT - TipRanks
Definium Therapeutics accelerates psychedelic treatment momentum with New York investor summit - Traders Union
Definium Therapeutics Highlights Clinical Advancements And Commercial Strategy For DT120 ODT - marketscreener.com
Transcript : Definium Therapeutics, Inc.Analyst/Investor Day - marketscreener.com
DFTX: DT120 targets major psychiatric disorders with pivotal data and commercial launch readiness in 2024 - TradingView
DFTX: DT-120 aims to transform psychiatric care with rapid, durable relief and broad market potential - TradingView
DFTX Maintained by Leerink Partners -- Price Target Raised to $3 - GuruFocus
Leerink Partners Issues Positive Forecast for Definium Therapeutics (NASDAQ:DFTX) Stock Price - MarketBeat
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day - Business Wire
DFTX News Today | Why did Definium Therapeutics stock go up today? - MarketBeat
0.78%
3.01%
자본화:
|
볼륨(24시간):